EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC-ND 4.0

Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation

Simon Chang iD, Claus H Gravholt iD, Anne Skakkebæk iD, Anna-Marie Bloch Münster iD, Yaseelan Palarasah iD

Andrology · 2026-03-27

DOI: 10.1111/andr.70220 ↗

At a glance

Journal article in Andrology, published online on 2026-03-27. Written by Simon Chang and 4 co-authors. Institution: Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark. 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk Fonden, Fonden af 17-12-1981, Danish Diabetes and Endocrine Academy.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Background

Klinefelter syndrome is associated with a markedly increased risk of venous thrombosis. While hypogonadism and metabolic dysfunction are known contributors, the role of the contact activation system in Klinefelter syndrome remains unexplored. contact activation system mediates crosstalk between coagulation, fibrinolysis, and inflammation and may contribute to thromboinflammatory risk.

Objective

To investigate whether contact activation system is dysregulated in Klinefelter syndrome and assess the influence of hypogonadism, body composition, and testosterone replacement therapy on contact activation system activity.

Methods

We conducted a longitudinal study including 22 testosterone‐treated Klinefelter syndrome, 15 untreated Klinefelter syndrome, and 14 age‐matched controls. Untreated Klinefelter syndrome initiated testosterone replacement therapy at baseline. Plasma levels of contact activation system proteins (coagulation factor XII, prekallikrein, high‐molecular‐weight kininogen, cleaved high‐molecular‐weight kininogen, and C1 esterase inhibitor were measured by enzyme‐linked immunosorbent assays. Contact activation system activity was assessed functional assays describing the endogenous kallikrein potential and contact‐induced thrombin generation. Associations with sex hormones and body composition were analyzed using mixed‐effects models.

Results

At baseline, untreated Klinefelter syndrome exhibited coagulation factor XII, prekallikrein, and C1 esterase inhibitor levels compared with controls. Following testosterone replacement therapy, untreated‐Klinefelter syndrome showed significant reductions in coagulation factor XII and C1 esterase inhibitor. Testosterone was inversely associated with coagulation factor XII, while body fat correlated positively with prekallikrein, endogenous kallikrein potential, and contact‐induced thrombin generation. Endogenous kallikrein potential and contact‐induced thrombin generation were not correlated, suggesting a bias toward inflammatory rather than procoagulant contact activation system activation.

Discussion

Contact activation system is dysregulated in hypogonadal Klinefelter syndrome and partially normalized by testosterone replacement therapy. contact activation system dysregulation in Klinefelter syndrome appears multifactorial, involving both hormonal and metabolic components. The strongest associations were with body fat, indicating that metabolic dysfunction may be a key regulator of contact activation system activity.

Conclusion

Inflammatory skew in contact activation system activation may contribute to thromboinflammatory risk in Klinefelter syndrome. Trial Registration Clinicaltrials.gov identifier: NCT02526628

Subjects

Author keywords

Klinefelter syndromecontact activationhypogonadismimmunothrombosistestosterone replacement therapy

Authors and institutions

  • Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
  • Unit for Thrombosis Research, Esbjerg Hospital-University Hospital of Southern Denmark, Esbjerg, Denmark.
  • Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
  • Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark.

ORCID profiles: Simon Chang, Claus H Gravholt, Anne Skakkebæk, Anna-Marie Bloch Münster, Yaseelan Palarasah

Funding

  • Novo Nordisk Fonden
  • Fonden af 17-12-1981
  • Danish Diabetes and Endocrine Academy
  • Danmarks Frie Forskningsfond
  • Sygesikringen danmark

Cite

APA

Chang, S., Gravholt, C. H., Skakkebæk, A., Münster, A. B., & Palarasah, Y. (2026). Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation. Andrology. https://doi.org/10.1111/andr.70220

Vancouver

Chang S, Gravholt CH, Skakkebæk A, Münster AB, Palarasah Y. Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation. Andrology. 2026. doi:10.1111/andr.70220

BibTeX
@article{Chang2026,
  author = {Chang, Simon and Gravholt, Claus H and Skakkebæk, Anne and Münster, Anna-Marie Bloch and Palarasah, Yaseelan},
  title = {Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation},
  journal = {Andrology},
  year = {2026},
  doi = {10.1111/andr.70220}
}
Start for free →